57 related articles for article (PubMed ID: 8332203)
1. Key statistician ousted as Waxman enters gp160 fray.
Macilwain C
Nature; 1993 Jul; 364(6436):374. PubMed ID: 8332203
[No Abstract] [Full Text] [Related]
2. Researchers recommend US AIDS vaccine trials.
Watson T
Nature; 1992 Nov; 360(6400):94. PubMed ID: 1436099
[No Abstract] [Full Text] [Related]
3. Vaccine compromise.
Nature; 1993 Apr; 362(6421):576. PubMed ID: 8464502
[No Abstract] [Full Text] [Related]
4. Vaccination with gp160 in HIV.
Oyaizu N; Chirmule N; Pahwa S
N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
[No Abstract] [Full Text] [Related]
5. Vaccination with gp160 in HIV.
Stanberry LR; Bernstein DI; Myers MG
N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
[No Abstract] [Full Text] [Related]
6. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
7. MicroGeneSys drops out of NIH trial for AIDS vaccine.
Macilwain C
Nature; 1993 Mar; 362(6418):277. PubMed ID: 8455703
[No Abstract] [Full Text] [Related]
8. Another reversal for the AIDS Vaccine Trial?
Science; 1993 May; 260(5112):1227. PubMed ID: 8493562
[No Abstract] [Full Text] [Related]
9. USA: therapeutic AIDS vaccine trial debated.
Rowe PM
Lancet; 1992 Nov; 340(8829):1216. PubMed ID: 1359275
[No Abstract] [Full Text] [Related]
10. Trial results thwart HIV-vaccine hopes.
McCarthy M
Lancet; 1996 Apr; 347(9009):1173. PubMed ID: 8609757
[No Abstract] [Full Text] [Related]
11. A genetically engineered protein may hold promise in the fight against the acquired immunodeficiency syndrome (AIDS).
J Am Osteopath Assoc; 1991 Nov; 91(11):1065. PubMed ID: 1752754
[No Abstract] [Full Text] [Related]
12. Properties of an HIV 'vaccine'.
Wahren B; Sandström E; Wigzell H
Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
[No Abstract] [Full Text] [Related]
13. US therapeutic AIDS vaccine trial.
Rowe PM
Lancet; 1993 Aug; 342(8870):543-4. PubMed ID: 8102676
[No Abstract] [Full Text] [Related]
14. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
15. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
Otteken A; Voss G; Hunsmann G
Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
[TBL] [Abstract][Full Text] [Related]
16. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
18. The presence or absence of gp120/gp160 bands on indeterminate western blots: predictive value for HIV seroconversion.
King R; Frey S; Beisha R; Van de Perre P; Karita E; Allen S
AIDS; 1993 Mar; 7(3):437-8. PubMed ID: 8471210
[No Abstract] [Full Text] [Related]
19. Update on HIV vaccines.
Meldorf M; Corey L
STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
[TBL] [Abstract][Full Text] [Related]
20. Novel single-round PCR and cloning of full-length envelope genes of HIV-1 may yield new insight into biomolecular antibacterial drug development.
McDonald R; Burnett V
J Virol Methods; 2005 Jun; 126(1-2):111-8. PubMed ID: 15847926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
